138 related articles for article (PubMed ID: 27868408)
1. [Effect of a novel EZH2 inhibitor GSK126 on prostate cancer cells].
Lin W; Chen Y; Zeng L; Ying R; Zhu F
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2016 May; 45(4):356-363. PubMed ID: 27868408
[TBL] [Abstract][Full Text] [Related]
2. The novel EZH2 inhibitor, GSK126, suppresses cell migration and angiogenesis via down-regulating VEGF-A.
Chen YT; Zhu F; Lin WR; Ying RB; Yang YP; Zeng LH
Cancer Chemother Pharmacol; 2016 Apr; 77(4):757-65. PubMed ID: 26898301
[TBL] [Abstract][Full Text] [Related]
3. Blocking EZH2 methylation transferase activity by GSK126 decreases stem cell-like myeloma cells.
Zeng D; Liu M; Pan J
Oncotarget; 2017 Jan; 8(2):3396-3411. PubMed ID: 27926488
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of EZH2 by chemo- and radiotherapy agents and small molecule inhibitors induces cell death in castration-resistant prostate cancer.
Wu C; Jin X; Yang J; Yang Y; He Y; Ding L; Pan Y; Chen S; Jiang J; Huang H
Oncotarget; 2016 Jan; 7(3):3440-52. PubMed ID: 26657505
[TBL] [Abstract][Full Text] [Related]
5. Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling.
Wang W; Wang L; Mizokami A; Shi J; Zou C; Dai J; Keller ET; Lu Y; Zhang J
Chin J Cancer; 2017 Mar; 36(1):35. PubMed ID: 28356132
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of EZH2 and activation of ERRγ synergistically suppresses gastric cancer by inhibiting FOXM1 signaling pathway.
Huang B; Mu P; Yu Y; Zhu W; Jiang T; Deng R; Feng G; Wen J; Zhu X; Deng Y
Gastric Cancer; 2021 Jan; 24(1):72-84. PubMed ID: 32529327
[TBL] [Abstract][Full Text] [Related]
7. Functional relevance of D,L-sulforaphane-mediated induction of vimentin and plasminogen activator inhibitor-1 in human prostate cancer cells.
Vyas AR; Singh SV
Eur J Nutr; 2014 Apr; 53(3):843-52. PubMed ID: 24092501
[TBL] [Abstract][Full Text] [Related]
8. PTEN Is Fundamental for Elimination of Leukemia Stem Cells Mediated by GSK126 Targeting EZH2 in Chronic Myelogenous Leukemia.
Zhou J; Nie D; Li J; Du X; Lu Y; Li Y; Liu C; Dai W; Wang Y; Jin Y; Pan J
Clin Cancer Res; 2018 Jan; 24(1):145-157. PubMed ID: 29070525
[No Abstract] [Full Text] [Related]
9. [Effect of enhancer of zeste homolog 2 inhibitor GSK126 on the proliferation and apoptosis of tongue squamous cell carcinoma].
Liu JN; Ma ZL; Su RJ; Huang KQ
Hua Xi Kou Qiang Yi Xue Za Zhi; 2020 Oct; 38(5):495-501. PubMed ID: 33085231
[TBL] [Abstract][Full Text] [Related]
10. Effect of SIRT1 Gene on Epithelial-Mesenchymal Transition of Human Prostate Cancer PC-3 Cells.
Cui Y; Li J; Zheng F; Ouyang Y; Chen X; Zhang L; Chen Y; Wang L; Mu S; Zhang H
Med Sci Monit; 2016 Feb; 22():380-6. PubMed ID: 26847404
[TBL] [Abstract][Full Text] [Related]
11. Effects of microRNA-183 on epithelial-mesenchymal transition, proliferation, migration, invasion and apoptosis in human pancreatic cancer SW1900 cells by targeting MTA1.
Lin X; Zheng L; Song H; Xiao J; Pan B; Chen H; Jin X; Yu H
Exp Mol Pathol; 2017 Jun; 102(3):522-532. PubMed ID: 28506766
[TBL] [Abstract][Full Text] [Related]
12. [Effects of the Rho-kinase inhibitor fasudil on the invasion, migration, and apoptosis of human prostate cancer PC3 and DU145 cells].
Gao QQ; Chen H; Chen Y; Xu ZP; Zhu LL; Yu W; Han YF; Dai YT
Zhonghua Nan Ke Xue; 2016 Jun; 22(6):483-490. PubMed ID: 28963834
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of the long non-coding RNA SPRY4-IT1 promotes tumor cell proliferation and invasion by activating EZH2 in hepatocellular carcinoma.
Zhou M; Zhang XY; Yu X
Biomed Pharmacother; 2017 Jan; 85():348-354. PubMed ID: 27899259
[TBL] [Abstract][Full Text] [Related]
14. Rottlerin inhibits cell growth and invasion via down-regulation of EZH2 in prostate cancer.
Zheng N; Wang L; Hou Y; Zhou X; He Y; Wang Z
Cell Cycle; 2018; 17(21-22):2460-2473. PubMed ID: 30394832
[TBL] [Abstract][Full Text] [Related]
15. Dysregulated lipid metabolism blunts the sensitivity of cancer cells to EZH2 inhibitor.
Zhang T; Guo Z; Huo X; Gong Y; Li C; Huang J; Wang Y; Feng H; Ma X; Jiang C; Yin Q; Xue L
EBioMedicine; 2022 Mar; 77():103872. PubMed ID: 35158113
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic histone methyltransferase EZH2: A novel prognostic marker with therapeutic potential in endometrial cancer.
Oki S; Sone K; Oda K; Hamamoto R; Ikemura M; Maeda D; Takeuchi M; Tanikawa M; Mori-Uchino M; Nagasaka K; Miyasaka A; Kashiyama T; Ikeda Y; Arimoto T; Kuramoto H; Wada-Hiraike O; Kawana K; Fukayama M; Osuga Y; Fujii T
Oncotarget; 2017 Jun; 8(25):40402-40411. PubMed ID: 28418882
[TBL] [Abstract][Full Text] [Related]
17. EZH2 Inhibitor GSK126 Suppresses Antitumor Immunity by Driving Production of Myeloid-Derived Suppressor Cells.
Huang S; Wang Z; Zhou J; Huang J; Zhou L; Luo J; Wan YY; Long H; Zhu B
Cancer Res; 2019 Apr; 79(8):2009-2020. PubMed ID: 30737232
[TBL] [Abstract][Full Text] [Related]
18. The involvement of FBP1 in prostate cancer cell epithelial mesenchymal transition, invasion and metastasis by regulating the MAPK signaling pathway.
Zhang YP; Liu KL; Yang Z; Lu BS; Qi JC; Han ZW; Yin YW; Zhang M; Chen DM; Wang XW; Li W; Xin H
Cell Cycle; 2019 Oct; 18(19):2432-2446. PubMed ID: 31448674
[TBL] [Abstract][Full Text] [Related]
19. Effects of miR-200c on the migration and invasion abilities of human prostate cancer Du145 cells and the corresponding mechanism.
Shi R; Xiao H; Yang T; Chang L; Tian Y; Wu B; Xu H
Front Med; 2014 Dec; 8(4):456-63. PubMed ID: 25363395
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Value of Twist-1, E-cadherin and EZH2 in Prostate Cancer: An Immunohistochemical Study.
Abdelrahman AE; Arafa SA; Ahmed RA
Turk Patoloji Derg; 2017; 1(1):198-210. PubMed ID: 28832071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
